• About us
• Contact

Advertisement

Organisation › Details

Medivir (Group)

Medivir is an emerging and profitable research-based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson's global sales of the hepatitis C pharmaceutical, Olysio. In addition, revenues for sales of Olysio in the Nordic region are generated through the company's own sales and marketing organisation. Medivir's research and development portfolio of pharmaceuticals is based on the company's expertise within polymerase and protease drugs targeting different disease areas. The company's current research and development is focused on infectious diseases, bone related disorders, neuropathic pain and oncology. Medivir is listed on the NASDAQ OMX Stockholm Mid Cap List. *

 

	Start	1988-01-01 splitoff
	Predecessor	Astra (Group)
	Industry	pharmaceutical
	Industry 2	cancer drug
	Person	Lind, Christine (Medivir 201704– CEO before EVP Strategic BusDev before LifeCellCorp + Merrill Lynch/BoAML in NY)
	Person 2	Prager, Niklas (Medivir 201409–201704 CEO before Merck & Co + Pfizer AB + Envirotainer AB + Qbtech AB LEFT 4/17)
	Region	Stockholm
	Country	Sweden
	Street	2 Blasieholmsgatan
	City	111 48 Stockholm
	Tel	+46-8-407-6430
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	SEK
	Annual sales	93,000,000 (turnover, net, consolidated (2016) 2016-12-31)
	Profit	-294,900,000 (2016-12-31)
	Cash	1,698,500,000 (2016-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Medivir (Group)

• [1] Immunicum AB. (10/26/21). "Press Release: Immunicum Appoints Lotta Ferm as Chief Financial Officer"....
• [2] Medivir AB. (10/25/21). "Press Release: Medivir Appoints Jens Lindberg as Chief Executive Officer". Stockholm....
• [3] Pharmanest AB. (5/18/18). "Press Release: Helena Jansson Appointed as New CEO of Pharmanest"....
• [4] Medivir AB. (12/10/17). "Press Release: Medivir Announces Janssen Decision to Terminate Its Simeprevir License effective June 2018". Stockholm....
• [5] Medivir AB. (11/10/17). "Press Release: Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development". Stockholm....
• [6] Medivir AB. (11/3/17). "Press Release: Medivir Appoints Erik Björk as Chief Financial Officer". Stockholm....
• [7] Medivir AB. (9/11/17). "Press Release: Medivir Announces Janssen to Discontinue Development of JNJ-4178 for Hepatitis C". Stockholm....
• [8] Medivir AB. (8/18/17). "Press Release: Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis". Stockholm & Hangzhou....
• [9] Medivir AB. (8/16/17). "Press Release: FDA Accepts Medivir´s IND Application for MIV-711, Enabling Clinical Development in the US". Stockholm....
• [10] Medivir AB. (3/16/17). "Press Release: Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development". Stockholm....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.